Every 10-Q that Acurx Pharmaceuticals, Inc. (ACXP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACXP filings page.
Acurx Pharmaceuticals is a clinical-stage biotech focused on novel DNA polymerase IIIC inhibitors, led by ibezapolstat for C. difficile infection. The company reported no revenue for the quarter and continues to operate at a loss while advancing its pipeline, including a new open-label pilot trial in recurrent CDI to inform planned Phase 3 development.
For the six months ended June 30, 2026, operating expenses were $4.0 million, down 10% from 2025, as a 21% decline in general and administrative costs offset higher research and development spending of $1.4 million. Net loss narrowed to $3.9 million from $4.4 million, and operating cash outflow was $3.1 million. Liquidity improved through equity financings: an April 2026 registered direct offering and ongoing sales under a $12.0 million equity line generated $6.2 million of cash in the first half, lifting cash to $10.7 million and shareholders’ equity to $8.2 million.
Management states that current cash is not sufficient to meet anticipated needs for at least 12 months from issuance of these financial statements and plans to seek additional equity and grant funding. The company discloses that these conditions raise substantial doubt about its ability to continue as a going concern. Acurx remains listed on Nasdaq following an earlier reverse stock split, while new Nasdaq market value requirements are currently stayed by the SEC.
Acurx Pharmaceuticals reported a Q1 2026 net loss of $1.68 million, an improvement from $2.15 million a year earlier, as both research and development and general and administrative expenses declined. R&D fell to $0.34 million and G&A to $1.37 million, reflecting lower manufacturing, consulting, professional, and legal costs.
Cash was $9.25 million and working capital $7.0 million as of March 31, 2026, with cumulative losses of about $77.0 million. Management states this cash will not fund operations for 12 months from issuance of the financial statements and raises “substantial doubt” about the company’s ability to continue as a going concern, expecting continued losses and relying on additional equity and grant funding.
The company continues developing ibezapolstat for C. difficile infection, launching a new open-label pilot trial in recurrent CDI and planning Phase 3 registration work. Liquidity efforts include an equity line of credit with Lincoln Park, under which $7.3 million has been raised, and an April 2026 registered direct offering and concurrent private placement providing approximately $2.5 million in gross proceeds plus new warrants.
Acurx Pharmaceuticals (ACXP) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $1,992,790 and a nine‑month net loss of $6,388,262. Cash was $5,906,802 as of September 30, 2025, with total assets of $6,105,211, liabilities of $2,468,175, and shareholders’ equity of $3,637,036. Operating expenses fell year over year, led by lower R&D ($429,691 vs. $1,198,184 in Q3 2024).
The company completed multiple financings in 2025: a January registered direct offering ($2.5M gross), a March registered direct offering with pre‑funded warrants ($1.1M gross), an equity line of credit with Lincoln Park of up to $12.0M (393,532 shares sold for $2.4M gross through Q3), and a June warrant‑inducement exercise yielding ~$2.5M net. Subsequent to quarter‑end, $1.4M was received from warrant exercises, and total ELOC sales reached 499,999 shares for ~$3.0M gross through November 11, 2025.
The company effected a 1‑for‑20 reverse stock split on August 4, 2025 and increased authorized common shares to 250,000,000 in September. Management disclosed “substantial doubt” about the ability to continue as a going concern. Shares outstanding were 1,800,299 as of September 30, 2025 and 2,085,363 as of November 11, 2025.
Acurx Pharmaceuticals (ACXP) reported $6.06 million in cash and total assets of $6.16 million at June 30, 2025, up from $3.71 million and $3.86 million at December 31, 2024, respectively. The company incurred a net loss of $2.25 million for the three months ended June 30, 2025 and $4.40 million for the six months ended June 30, 2025, which are both smaller than the comparable 2024 periods. Research and development expense declined to $524,210 in the quarter, reducing total operating expenses to $2.27 million.
Cash used in operating activities for the six months was $3.72 million while financings provided $6.08 million of net cash in the period, including registered offerings, an equity line of credit and a warrant inducement. Management warns that as of June 30, 2025 the Company believed its cash was insufficient to meet anticipated cash requirements for at least 12 months, raising substantial doubt about its ability to continue as a going concern. The filing also discloses Nasdaq notices for minimum stockholders' equity and minimum bid price noncompliance and a 1-for-20 reverse stock split effected in August 2025.